FDA’s pharma boss overrules scientists to approve controversial muscular dysrophy drug from Sarepta

Raw Story

Bowing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency’s own reviewers questioned the drug’s efficacy. The FDA’s lead reviewer, Dr....

view Raw Story